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ttp://dx.doi.org/10.1016/j.ajpath.2013.11.014Pancreatic ductal adenocarcinoma (PDAC) is associated with a high incidence of hepatic metastases, as
well as occasional pulmonarymetastases. To delineate the potential role of cancer stem cells (CSCs) in PDAC
metastasis, human PDAC cells were injected into the spleen of mice. The characteristics and expression of
markers associated with CSC and epithelialemesenchymal transition (EMT) of metastatic cells that
developed in the liver and lung were then compared with parental cells. The metastatic cells were polyg-
onal, and larger than parental cells. Metastatic cells also exhibited decreased proliferation and increased
adhesion to extracellular matrices, as well as enhanced migration and invasion in vitro and increased
metastatic capacity in vivo. The CSC markers ALDH1A1, ABCG2, and nestin were expressed at high levels in
metastatic cells and exhibited changes consistent with EMT (eg, decreased E-cadherin expression).
Moreover, metastatic cells readily formed spheres in culture and exhibited an increased side population by
ﬂowanalysis. Nestin andABCG2were also expressed at high levels inmetastatic lesions fromPDACpatients,
and silencing nestinwith shRNA in PDAC cells derived from lungmetastases resulted in amarkeddecrease in
the capacity of the cells to form spheres and to yield pulmonary or hepaticmetastases. Thus, themetastatic
potential of human PDAC cells correlates with CSCs and with EMT characteristics and is dependent on nestin
expression. (Am J Pathol 2014, 184: 674e685; http://dx.doi.org/10.1016/j.ajpath.2013.11.014)Supported in part by the Japan Society for the Promotion of Science grant-
in-aid 25462127 and 25461027 (Y.M. and T.I.), the Pancreas Research
Foundation of Japan (H.Y.), and NIH grant R37-CA-075059 (M.K.).
Disclosures: None declared.Pancreatic ductal adenocarcinoma (PDAC) is an aggressive
malignancy with a high incidence of distant metastasis.1 The
metastatic process involves a series of complex biological
processes, including migration, invasion, adhesion, and sur-
vival.2 Furthermore, the extracellular matrix, interstitial cells,
blood and lymph vessels, nerve ﬁbers, and immune cells
contribute to these processes. It is difﬁcult to completely
resolve the pathways that promote invasion and metastasis of
PDACcells, but elucidating themechanisms that contribute to
their enhanced metastatic efﬁciency is important for devel-
opment of novel therapeutic approaches. Accordingly, a va-
riety of mouse models, ranging from orthotopic models to
genetically engineered mice, have been developed to study
the metastatic processes that govern PDAC metastasis.
Injection of human PDAC cells into the spleen of nude
mice or NOD/SCID mice is a model that yields a small
number of metastatic nodules in the liver.3 By contrast, in
the recently developed NOD/Shi-scid IL2Rgnull (NOG)
mice (which have severe immunodeﬁciency, includingstigative Pathology.
.defects in T, B, natural killer, and dendritic cell function)
human pancreatic and colorectal cancer cells easily proliferate
and metastasize to the liver after intrasplenic injection.4 It is
not known, however, whether cancer stem cells (CSCs) have a
role in the enhanced metastatic propensity of NOG mice.
CSCs exhibit pluripotency, have the potential to self-renew,
and are crucially important in cancer cell growth, invasion,
metastasis, and recurrence.5e7 CSCs preferentially spread to
distant organs and contribute to the formation of lesions that
phenocopy the primary tumor.8
Given these observations, it has been suggested that tar-
geting CSCs could provide a new therapeutic strategy in
cancer.9 It is therefore important to examine the temporal
and spatial alterations of CSCs in metastatic lesions in vivo.
Pancreatic CSCs in Metastatic FociFurthermore, epithelialemesenchymal transition (EMT), a
fundamental mechanism controlling multiple events during
metastasis,10 may generate additional CSCs endowed with a
more invasive, migratory, and metastatic phenotype.11 We
reasoned that NOG mice would be useful for assessing the
role of CSCs in the metastatic process in PDAC, because
this model avoids the complexity engendered by an active
immune system.
In the present study, we analyzed pathological features of
metastatic tumors originating from human PDAC cells. Met-
astatic PDAC cells exhibited lower growth rates, but higher
migration and metastatic abilities. The metastatic lesions
containedmore CSCs than did primary tumors, and these cells
exhibited a mesenchymal phenotype. Moreover, inhibition of
one of the CSC markers, nestin, in metastatic PDAC cells
reduced sphere formation in vitro and metastasis in vivo.
Materials and Methods
Materials
Antibodies were purchased as follows: mouse monoclonal
antiecytokeratin 19 (CK-19) antibody from Boehringer
Mannheim Biochemical (Roche Applied Science, Mannheim,
Germany); mousemonoclonal antiehuman leukocyte antigen
(HLA) class I-A, B, and C antibody from Hokudo (Sapporo,
Japan); mouse monoclonal antieE-cadherin, mouse mono-
clonal anti-vimentin, mouse monoclonal antieKi-67, and
mouse monoclonal anti-CD68 antibodies from Dako (Kyoto,
Japan; Carpinteria, CA); mouse monoclonal anti-ABCG2,
rabbit polyclonal anti-ALDH1A1, mouse monoclonal anti-
CD3, mouse monoclonal anti-CD11c, rabbit polyclonal
antiec-Met, and rabbit polyclonal anti-CXCR4 antibodies
fromAbcam (Cambridge,UK);mousemonoclonal anti-CD44
and mouse monoclonal anti-nestin antibodies from R&D
Systems (Minneapolis, MN); mouse monoclonal anti-CD133,
goat polyclonal anti-nestin, mouse monoclonal anti-GAPDH,
andmousemonoclonal anti-CD20 antibodies fromSanta Cruz
Biotechnology (Santa Cruz, CA); and rat monoclonal anti-
eMAC-2 antibody from Cedarlane Laboratories (Burlington,
ON, Canada). Matrigel invasion chambers were purchased
from BD Biosciences (San Jose, CA), and various chemicals
and reagents from Sigma-Aldrich (St. Louis, MO).
Human PDAC Cell Lines
Twelve human PDAC cell lines were obtained from the Cell
Resource Center for Biomedical Research, Institute of
Development, Aging and Cancer, Tohoku University (Sen-
dai, Japan; ACBR-1, AsPC-1, KLM-1, MIAPaCa-2, PANC-
1, PK-1, PK-45H, PK-45P, PK-59, PK-8, and PK-9) and from
the ATCC (Manassas, VA; Capan-1). Cells were cultured in
RPMI 1640medium containing 10% fetal bovine serum (15%
for Capan-1 cells). The PANC-1, PK-45H, and KLM-1 cell
lines were authenticated by short tandem repeat proﬁling
analysis (March 2012; data not shown).The American Journal of Pathology - ajp.amjpathol.orgIntrasplenic, Intrapancreatic, and Intravenous Tumor
Models
PANC-1 or PK-45Hcells (1 105 cells)were injected into the
spleen of 6-week-old male NOG mice (nZ 12 per cell line)
(Central Institute for Experimental Animals, Kanagawa,
Japan) and BALB/cA Jcl-nu/nu nude mice (nZ 12 per cell
line) (CLEA Japan, Tokyo, Japan). The spleen was resected
1 minute later. After 1 day and after 2, 4, and 8 weeks, three
mice per time point were euthanized, and the liver, pancreas,
lungs, heart, brain, and kidneys were excised.
Orthotopic implantations were performed by injecting
1  105 cells into the tail portion of the pancreas of NOG
mice (n Z 3 mice per cell line), which were sacriﬁced 8
weeks later. Tail-vein injections (1  105 cells) were per-
formed in NOG mice (nZ 6 mice per cell line), which were
sacriﬁced 8 weeks later. All animal experiments were con-
ducted according to the institutional animal care guidelines
of the Nippon Medical School Animal Ethical Committee.
Immunohistochemistry
Parafﬁn-embedded sections were subjected to immunostain-
ing using a Histoﬁne Simple Stain MAX PO kit (Nichirei
Biosciences, Tokyo, Japan). For aldehyde dehydrogenase 1
familymemberA1 (ALDH1A1), E-cadherin, vimentin, ATP-
binding cassette subfamily G member 2 (ABCG2), CD44,
CD133, Ki-67, CD3, CD20, and CD11c, tissue sections were
preheated in 10 mmol/L of citrate buffer (pH 6.0). For MAC-
2, tissue sectionswere treated in 0.1%protease for 10minutes.
Tissue sections were incubated overnight with the following
antibodies and dilutions: anti-ALDH1A1 (1:100), antie
CK-19 (1:100), anti-HLA (1:100), antieE-cadherin (1:100),
anti-vimentin (1:500), anti-ABCG2 (1:100), anti-CD44
(1:10,000), anti-CD133 (1:1500), mouse monoclonal anti-
nestin (1:200), antieKi-67 (1:100), anti-CD3 (1:400), anti-
CD20 (1:800), antieMAC-2 (1:200), anti-CD68 (1:50), and
anti-CD11c (1:100). Negative controls were prepared by
omitting the primary antibody. For analysis of the immuno-
staining results, we captured ﬁve images in each specimen at
200 magniﬁcation and then measured the areas of positive
cells using WinROOF image analysis software version 6.1.3
(Mitani, Tokyo, Japan). We determined the percentage of
HLAþ cancer area as described previously,9 and then deter-
mined the ratios of positive immunostaining for ALDH1A1,
ABCG2, CD44, nestin, Ki-67, E-cadherin, and vimentin to
HLAþ cancer cell area in metastatic foci.
Detection of Human-Speciﬁc or Mouse-Speciﬁc
Mitochondrial Genes
We performed PCR with human-speciﬁc and mouse-
speciﬁc mitochondrial primers and a TaKaRa Ex Taq kit,
Hot Start version (Takara Bio, Otsu, Japan). The human
forward and reverse primers were, respectively, 50-TATT-
GCAGCCCTAGCAGCACTCCA-30 (15,311 to 15,334)675
Matsuda et aland 50-AGAATGAGGAGGTCTGCGGC-30 [15,732 to
15,751, 441 bp; NC_001807. (This reference sequence was
removed fromGenbank and replacedwith recordNC_012920
as the accepted reference sequence for Homo sapiens mito-
chondrion; there is only a single nucleotide difference in the
forward primer and the currently recognized reference
sequence.)]. The mouse forward and reverse primers were,
respectively, 50-GCACTGAAAATGCTTAGATGGATAA-
TT-G-30 (28 to 55) and 50-CCTCTC-ATAAACGGATGTC-
TA-G-30 (954 to 975, 948 bp; NC_005089).12
Establishment of PDAC Cells from Metastatic Tumors
NOGmiceweregiven a single intrasplenic injectionof 1 105
PANC-1 or PK-45H cells. Eight weeks later, the mice were
euthanized and the liver and lungs were removed. Metastatic
foci were cut into 1-mm3 cubes, and tumor fragments
dispersed in a medium containing antibiotics (400 U/mL
penicillin and 400 mg/mL kanamycin). Metastatic PANC-1 or
PK-45H cells from liver or lung (referred to here as PANC-
liver, PANC-lung, PK-liver, and PK-lung cells) were
conﬁrmed as being of human origin, using human- or mouse-
speciﬁc mitochondrial gene primers as described above.
Cell Growth Assays
Cell growth was monitored with a nonradioactive prolifer-
ation assay using a WST-8 cell-counting kit (Dojindo Mo-
lecular Technologies, Kumamoto, Japan; Rockville, MD).
Experiments were performed in triplicate.
Cell Adhesion, Migration, and Invasion Assays
Cell adhesion to extracellular matrices (bovine type I
collagen, human type IV collagen, bovine ﬁbronectin, and
murine laminin) was determined as described previously.9
Single-cell movement was analyzed using time-lapse mi-
croscopy, as described previously.13 Invasion assays were
performed using a modiﬁed Boyden chamber technique
with Matrigel-coated inserts.9 Experiments were performed
in triplicate.
RT-qPCR
Quantitative RT-PCR (RT-qPCR) was performed using Taq-
Man Fast Universal PCR master mix and TaqMan gene
expression assays (Life Technologies, Carlsbad, CA) for
ALDH1A1 (Hs00946916_m1), E-cadherin (Hs01013953_m1),
vimentin (Hs00185584_m1), ABCG2 (Hs01053790_m1),
CD44 (Hs00153304_m1), CD133 (Hs01009238_m1), nestin
(Hs00707120_s1), c-Met (alias hepatocyte growth factor re-
ceptor) (Hs01565584_m1), hepatocyte growth factor (HGF)
(Hs00300159_m1), and 18S rRNA (Hs99999901_s1). RT-
qPCR results were expressed as the ratio of target to 18S
rRNA. Gene expression measurements were performed in
triplicate.676Western Blot Analysis
Proteins were subjected to SDS-PAGE under nonreducing
conditions. Membranes were incubated with goat polyclonal
anti-nestin antibody (1:1000) and then with donkey anti-
goat IgG (1:4000). Membranes were reblotted with anti-
GAPDH antibody (1:5000).
Sphere-Formation Assay
Cells (1  103/well) were plated in a 24-well plate with an
ultralow-attachment surface and supplemented with basic
ﬁbroblast growth factor (bFGF; 10 ng/mL) and pro-
epidermal growth factor (EGF; 20 ng/mL).14 After 5 days,
the number of spheres was counted using phase-contrast
microscopy. Experiments were performed in triplicate.
Flow Cytometry
Cells were stained with Hoechst dye 33342 (5 mg) to identify
the side-population cells.13 Verapamil (30 mg/mL) was used
to verify speciﬁcity of the side-population population.
Monoclonal mouse IgG1 anti-nestin antibody was labeled
with Alexa Fluor 488 using a Zenon antibody labeling kit
(Life Technologies). Antibodies for ALDH1A1 (rabbit),
ABCG2 (mouse IgG2a), CD44 (mouse IgG2a), CD133
(mouse), c-Met (rabbit), and CXCR4 (rabbit) were labeled
with allophycocyanin. Cells were incubated for 20 minutes at
4C in 10% human serum, and then incubated (5 105 cells/
50 mL) with each antibody for 30 minutes at room tempera-
ture. Dead cells were labeled with the addition of 1 mg pro-
pidium iodide.We prepared rabbit IgG isotype control-treated
cells as negative controls. Expression of each protein was
analyzed using a BD FACSAria II ﬂow cytometer (BD Bio-
sciences). Experiments were performed in triplicate.
Human PDAC Autopsy Cases
Tissue sections from 12 autopsy cases (4 male, 8 female) with
PDAC at Nippon Medical School Hospital (Tokyo, Japan)
from 1995 to 2010 were obtained for this study. Median age
was 73.9 years (range, 58 to 88 years). All 12 patients had liver
metastases, 8 had lung metastases, 11 had lymph node me-
tastases, and 9 had omental metastases. The study was con-
ducted in accordance with the principles embodied in the
2008 Declaration of Helsinki. Only tissues that exhibited
histological integrity were used for immunostaining.
Generation of Nestin shRNA-Expressing Transfectants
Nestin shRNA expression vector and sham vector9 were
transfected into PANC-liver and PANC-lung cells using
FuGENE HD transfection reagent (Roche Diagnostics,
Indianapolis, IN). Independent colonies were isolated by
ring cloning. shRNA transfection efﬁciency was conﬁrmed
by RT-qPCR and Western blotting.ajp.amjpathol.org - The American Journal of Pathology
Pancreatic CSCs in Metastatic FociStatistical Analysis
Data were compared by one-way analysis of variance and
c2 test using the StatView J software package version 5.0
(SAS Institute, Cary, NC). P < 0.05 was considered sta-
tistically signiﬁcant.
Results
Formation of Metastatic PDAC Tumors in
Immunodeﬁcient Mice
PANC-1 andPK-45HhumanPDACcellswere injected into the
spleen of NOG mice. Macroscopically, PANC-1 cells yielded
small, white hepatic nodules at 4 weeks, and the liver was
mostly replaced by metastatic tumors at 8 weeks (Figure 1A).
Similar results were observed with PK-45H cells (data not
shown). In addition, nondescript red nodules were detected inThe American Journal of Pathology - ajp.amjpathol.orglung of NOG mice at 8 weeks with both PANC-1 (Figure 1A)
andPK-45H (data not shown) cells. Therewere nomacroscopic
metastases in other organs and no other signiﬁcant changes.
Microscopic analysis revealed the presence of metastatic
cancer cells in liver of NOGmice at 8 weeks after intrasplenic
injection of PANC-1 or PK-45H cells (Supplemental
Figure S1A). IHC analysis using antieCK-19 and anti-HLA
revealed that PANC-1 cells metastasized to liver, lung,
pancreas, kidney, and heart (Supplemental Figure S1, BeG),
whereas PK-45H cells metastasized only to lung and pancreas
(data not shown). In the liver, PANC-1 cells formed alveolar
structures, and PK-45H cells formed gland-like structures
(Supplemental Figure S1H). The extent of hepatic and lung
metastases increased over time (Figure 1B), with HLAþ cells
detectable in liver of all NOGmice on days 1 through 56 after
intrasplenic injection (Supplemental Table S1).
To conﬁrm the presence of PANC-1 cells in NOG mice,
PCR for human- and mouse-speciﬁc mtDNA was performedFigure 1 A: Macroscopic appearance of liver
and lung after intrasplenic injection of PANC-1
human PDAC cells. Arrows indicate metastatic
tumors. B and C: Metastatic tumor areas were
calculated as a percentage of HLAþ areas in liver
and lung. D and E: Morphological changes in the
cells derived from metastatic tumors of NOG mice
(phase-contrast microscopy) included cells with
large and polygonal morphology (arrows). Data
are expressed as means  SEM. *P < 0.05 versus
other time points. Scale bar Z 100 mm.
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Matsuda et al(Supplemental Figure S2A). Human mtDNA was detected
in liver at 1 day and 2 weeks, and in liver and lung at 4
weeks. Moreover, at 8 weeks, human mtDNA was detected
in liver, lung, heart, and kidney of NOG mice, but not in
brain. Conversely, mouse-speciﬁc mtDNA was detected in
all of the organs, but not in PANC-1 cells.
In contrast to our ﬁndings in NOG mice, at 24 hours after
injection of PANC-1 cells into the spleen of nude mice,
human-speciﬁc mtDNA was detected in the liver, but these
cells did not yield macroscopically visible metastases in
liver. Moreover, there were no visible metastases, and
human-speciﬁc mtDNA was not detected by PCR in any of
the above organs, all of which were analyzed at weekly
intervals for 8 weeks (data not shown).678Isolation and Characterization of Human PDAC Cells
Derived from Metastatic Tumors Arising in NOG Mice
To analyze the cell behavior of metastatic tumors, we har-
vested PANC-1 and PK-45H cells from liver and lung tumors
ofNOGmice at 8weeks after xenotransplantation,when there
was signiﬁcant metastatic burden in both tissues in both cell
lines (Figure 1, B and C). PANC-1 and PK-45H cells derived
from liver tumors (PANC-liver and PK-liver) and from lung
tumors (PANC-lung and PK-lung) expressed human-speciﬁc
mitochondrial genes, but not mouse-speciﬁc mitochondrial
genes (Supplemental Figure S2, B and C). Compared with
parental PANC-1 or PK-45H cells, some of the cells derived
from metastatic tumors of NOG mice (PANC-liver, PANC-Figure 2 Cell growth, attachment, migration,
and invasion assays of human PDAC cells derived
from metastatic tumors of NOG mice. A and B: Cell
growth of PANC-1 and PK-45H was analyzed by a
WST-8 cell-counting assay. C and D: Attachment
assay of cells to extracellular matrices. EeG:
Single-cell movement was monitored by time-lapse
microscopy. HeJ: Cell invasion was analyzed by
Boyden chamber assay. Data are expressed as
means  SEM. *P < 0.05, **P < 0.01 versus
parental cells. yP < 0.05 versus liver cells. Original
magniﬁcation, 100 (E); 200 (H).
ajp.amjpathol.org - The American Journal of Pathology
Pancreatic CSCs in Metastatic Focilung, PK-liver, and PK-lung) were very large and exhibited a
polygonal morphology (Figure 1, D and E).
Compared with parental cells, cells derived from pulmo-
nary or hepatic metastatic lesions exhibited attenuated growth
rates, especially in the case of PK-lung cells (Figure 2, A and
B), but increased cell attachment to components of the
extracellular matrix, including type I and IV collagen and
ﬁbronectin (Figure 2, C and D). PANC-liver and PANC-lung
cells also exhibited increased attachment to laminin, whereas
the attachment of PK-liver and PK-lung cells was not altered
by laminin (Figure 2, C andD). By contrast, PANC-liver cells
exhibited increased motility, compared with parental cells
(Figure 2, E and F), and PANC-lung cells exhibited greater
motility than PANC-liver cells (Figure 2, E and F). In the case
of PK-45H cells, only PK-lung cells exhibited signiﬁcantly
increased motility, compared with parental cells (Figure 2G).
Moreover, in Boyden chamber invasion assays, all four
metastatic cell lines exhibited increased invasion, compared
with the corresponding parental cells (Figure 2, HeJ).
Tail-Vein Injection of Metastatic Cells
To assess the metastatic potential of cells derived from
metastatic foci, we performed tail-vein injection of PANC-
liver and PANC-lung cells in NOG mice. At 8 weeks afterThe American Journal of Pathology - ajp.amjpathol.orginjection, PANC-liver and PANC-lung cells formed more
macroscopically visible tumors in liver and lung, compared
with parental PANC-1 cells (Figure 3, A and B). Some of
the hepatic lesions were very large (Figure 3A), whereas the
pulmonary lesions appeared as small red spots, indicative of
small areas of hemorrhage (Figure 3B). Compared with
parental cells, which formed metastases in only 50% of the
cases, there were more HLAþ areas in liver and lung after
injection of PANC-liver and PANC-lung cells, and both
organs exhibited metastatic lesions in 100% of cases
(Figure 3, C and D, and Supplemental Table S2). There
were no tumors and other signiﬁcant changes in the brain.
To conﬁrm these results, we performed studies using an
orthotopic model. Compared with parental cells, PANC-
liver cells formed larger metastatic lesions in both liver and
lung, whereas PANC-lung cells formed larger metastatic
lesions in lung (Figure 3E). Moreover, PK-liver and PK-
lung cells formed larger metastatic lesions in liver and
lung, respectively, compared with parental cells (Figure 3F).
PDAC Cells Derived from Metastatic Lesions Exhibit
Features Suggestive of Cancer Stem Cells and EMT
In view of the potential role of CSC and EMT in metastasis,
we next sought to determine whether our metastatic cellsFigure 3 In vivo metastasis of human PDAC
cells derived from metastatic tumors of NOG mice.
A and B: Tumors of liver (arrows, A) and lung
(arrowheads, B) after tail-vein injection of cells.
C: HLAþ metastatic tumor cells (arrowheads) in
liver and lung. D: Metastatic tumor area, calcu-
lated as the HLAþ area divided by the total area
(liver, lung, or kidney) and then multiplied by 100.
E and F: Metastatic tumor areas in liver, lung, or
kidney after orthotopic implantation of the cells.
Data are expressed as means  SEM. *P < 0.05
versus PANC-1 cells. Scale bar Z 100 mm.
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Accordingly, we performed sphere-formation assays and
side-population analysis with all four cell lines. Cells were
plated in ultra-low attachment plates supplemented with
EGF and FGF-2, and sphere formation was monitored
(Figure 4A). PANC-liver, PANC-lung, PK-liver, and PK-
lung cells formed a greater number of spheres, compared
with their parental cells (Figure 4, B and C). Moreover,
PANC-liver and PANC-lung cells exhibited increased side-
population fraction, compared with parental cells (Figure 4,
D and E). By contrast, in PK-45H cells no side-population
cells were detected by ﬂow cytometry.
Next, we examined expression of CSC markers. As deter-
mined by RT-qPCR, aldehyde dehydrogenase mRNA level
was increased in PANC-liver, PANC-lung, PK-liver, and PK-
lung cells, compared with the corresponding parental cells
(Figure 4, F and G). Nestin mRNA level was increased in
PANC-lung, PANC-liver, and PK-lung cells, but not in PK-
liver cells, compared with the corresponding parental cells
(Figure 4, H and I). Moreover, ABCG2 expression was
increased in PANC-lung but not PANC-liver cells, and in both
PK-liver and PK-lung cells (Figure 4, J and K). However, the680expression of CD44, CD133, c-Met, and HGF (which also
have been described as CSC markers) was similar in parental
and metastatic cells (Supplemental Figure S3, AeG), except
that CD133 mRNA was increased in PK-liver cells and HGF
mRNA was not detectable in PK-45H cells. Flow cytometry
analysis revealed higher nestin expression in metastatic cells,
compared with parental cells (Supplemental Figure S4A).
Furthermore, various levels of coexpression of nestin and
other CSC markers were detected in metastatic PANC-1 and
PK-45H cells (Supplemental Figure S4, BeG).
To conﬁrm the increase of CSCs in metastatic lesions, we
performed IHC analysis for CSC markers and for the cell
proliferationmarkerKi-67at 8weeksafter xenotransplantation.
Metastatic tumor cells in liver exhibited various levels of
immunoreactivity for ALDH1A1 and nestin in the cytoplasm
and on the cell membrane, for ABCG2 and CD44 on the cell
membrane, and for Ki-67 in the nucleus (Figure 5A).
Next, we analyzed the percentage of CSC markere
positive cells in NOG mice in each organ at each time point
(Figure 5, BeF). At 8 weeks after xenotransplantation, the
percentage of nestinþ cells was increased in lung, compared
with pancreas and liver (Figure 5C). In liver, the percentageFigure 4 Stemness of human PDAC cells
derived from metastatic tumors of NOG mice. A:
Sphere-forming assay of cells. Spheres (arrows)
are shown at higher magniﬁcation in the insets.
B and C: Number of spheres per well for PANC-1
and PK-45H cells. D and E: Proportion of side-
population fraction (pink) and major population
(orange), as determined by ﬂow cytometry (D) and
quantiﬁcation (E). FeK: Expression of the CSC
markers ALDH1A1 (F and G), nestin (H and I), and
ABCG2 (J and K). *P < 0.05, **P < 0.01 versus
parental cells. yyP < 0.01 versus metastatic cells
from liver. Original magniﬁcation: 40 (main
images); 100 (insets).
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Figure 5 A: IHC analyses for the CSC markers ALDH1A1, nestin, ABCG2, and CD44 and for the proliferation
marker Ki-67 in metastatic tumors of NOG mice at 8 weeks. Positive cells in liver tumors are indicated by arrows.
BeF: Percentage of CSC markerepositive cells relative to HLAþ tumor cells in pancreas, liver, and lung of NOG
mice at 2, 4, and 8 weeks after xenotransplantation. G: Western blots for human nestin in liver and lung tissues
of NOG mice. Data are expressed as means  SEM. Pancreas: 2 weeks, nZ 1; 4 weeks, nZ 5, 8 weeks, nZ 6;
liver: 2 weeks, nZ 6; 4 weeks, nZ 6; 8 weeks, nZ 6; lung: 2 weeks, nZ 0; 4 weeks, nZ 2; 8 weeks, nZ 5.
Sample numbers differ because of different tumor-formation abilities in each organ. *P < 0.05, **P < 0.01.
Scale bar Z 100 mm.
Pancreatic CSCs in Metastatic Fociof nestinþ cells was decreased at 8 weeks, compared with 2
weeks (Figure 5C), and this decrease was conﬁrmed by
immunoblotting (Figure 5G). Similarly, the percentage of
ABCG2þ cells was decreased in liver at 4 and 8 weeks,
compared with 2 weeks (Figure 5D). By contrast, the per-
centage of ALDH1A1þ, CD44þ, and Ki-67þ cells was
similar in pancreas, liver, and lung (Figure 5, B, E and F),
whereas no CD133 immunoreactivity was detected in all
specimens. Thus, nestin and ABCG2 levels were increased
in metastatic cells, and remained elevated in lung metasta-
ses, but decreased over time in liver metastases.EMT Markers in PDAC Cells Derived from Metastatic
Tumors
To assess the role of EMT in the metastatic process, we next
examined expression of EMT markers. E-cadherin mRNA
levels in all four metastatic cell lines were lower than in the
corresponding parental cells, and were lowest in PANC-
lung and PK-lung cells (Figure 6, A and B). By contrast,
vimentin mRNA levels were generally similar in metastatic
and parental cells (Figure 6, C and D), except that PK-liver
cells expressed higher levels of vimentin, compared withThe American Journal of Pathology - ajp.amjpathol.orgparental and PK-lung cells (Figure 6D). Moreover, at 8
weeks after splenic injection, hepatic metastases exhibited
relatively low-intensity E-cadherin immunoreactivity on the
cell membrane (Figure 6E) and strong vimentin immuno-
reactivity in the cytoplasm (Figure 6F), whereas the per-
centage of E-cadherinþ cells relative to HLAþ tumor cells
decreased in lung, compared with pancreas and liver
(Figure 6G). By contrast, strong vimentin immunoreactivity
persisted at 8 weeks in all three organs (Figure 6H).Expression of CSC and EMT Markers in Human PDAC
Autopsy Cases
We next sought to compare the immunostaining of CSC and
EMT markers in primary and metastatic lesions in 12 au-
topsy cases of PDAC patients. Each CSC or EMT marker
was expressed in the different types of cells at various levels
in human nontumorous pancreatic tissues (Supplemental
Figure S5). CD44, CD133, and E-cadherin were expressed
in ductal cells; CD44 and E-cadherin were expressed in
acinar cells; vimentin was expressed in mesenchymal cells;
and nestin was not expressed. In addition to hepatic me-
tastases, we examined other metastatic lesions (lymph node,681
Figure 6 AeD: Expression of the EMT markers
E-cadherin and vimentin in cells derived from
metastatic foci of NOG mice. E and F: IHC analysis
for E-cadherin and vimentin in metastatic liver
tumors of NOG mice at 8 weeks. Positive cells are
indicated by arrows. G and H: Percentage of EMT
markerepositive cells relative to HLAþ tumor cells
in liver and lung of NOG mice. *P < 0.05 versus
lung cells. **P < 0.01 versus parental cells.
yyP < 0.01 versus metastatic cells from liver. Scale
bar Z 100 mm.
Matsuda et allung, and omentum). Immunoreactivity of nestin and ABCG2
was increased in metastatic lesions, compared with primary
lesions, whereas E-cadherin immunostaining was decreased
(Supplemental Figure S6A). The percentage of nestinþ cells
was not signiﬁcantly increased in liver lesions, but was signif-
icantly increased in other metastatic lesions (Supplemental
Figure S6C). By contrast, ABCG2 immunoreactivity was
signiﬁcantly increased (Supplemental Figure S6D), and
E-cadherin immunoreactivity was signiﬁcantly decreased,
in all tested metastases (Supplemental Figure S6G). How-
ever, ALDH1A1, CD44, CD133, and vimentin immuno-
reactivity did not differ signiﬁcantly between the metastatic
lesions and the primary PDAC tumor (Supplemental
Figure S6, B, E, F, and H).
Effects of Nestin Silencing on Sphere Formation and
Metastasis
In view of the increased expression of nestin in metastasis-
derived cell lines and in both mouse and human metastatic
lesions, we next assessed the consequences of nestin
knockdown on sphere formation and metastasis. shRNAs
targeting nestin were stably transfected into PANC-lung
cells, and nestin mRNA and protein levels were assessed682in scrambled sequence subcloned sham vector stably
transfected cells (Sc-1 and Sc-10) and in nestin shRNA
stably transfected cells (Sh-1 and Sh-2), using RT-qPCR
and immunoblotting (Figure 7, A and B). Selected clones
were then tested for their ability to form spheres. Nestin
shRNAetransfected cells exhibited decreased sphere for-
mation, compared with parental and Sc cells (Supplemental
Figure S7, A and B), and decreased slug mRNA expression
(Supplemental Figure S7C). By contrast, expression of
snail, zeb1, and zeb2 mRNA was not altered (Supplemental
Figure S7, DeF), and twist mRNA was not detected in these
cells (data not shown). PANC-1 exhibited high nestin
expression levels, but KLM-1 and PK-8 exhibited no or low
nestin expression levels. These observations suggest that
nestin may regulate EMT by modulating slug expression.
Next, the same cells were injected into the spleen of NOG
mice (nZ 4 per cell line). At 6 weeks after injection, some
mice exhibited weight loss (approximately 10%), and there-
fore the experiment was terminated at that time point. PANC-
lung cells exhibited more aggressive metastatic tumors in
liver (Figure 7C), compared with parental PANC-1 cells
(Figure 1A). However, PANC-lung cells transfected
with shRNA targeting nestin (Sh-1 and Sh-2) exhibited a
dramatic decrease in liver metastasis, compared with parentalajp.amjpathol.org - The American Journal of Pathology
Figure 7 Inhibition of metastasis using shRNA
targeting nestin of PANC lung cells. Stable trans-
fection of shRNA targeting nestin into PANC lung
cells. A: RT-qPCR analysis of nestin in shRNA-
transfected clones. B: Western blots for nestin
conﬁrm decreased expression in shRNA-transfected
clones. C and D: Stable transfection of shRNA
targeting nestin suppressed liver and lung metas-
tases of NOG mice. Arrows indicate metastatic
tumors (in the liver, C) or hemorrhage (in the lung,
D). E and F: Metastatic tumor areas in liver and
lung in shRNA-transfected clones. G: IHC analysis
of nestin in hepatic metastases. Scale bar Z 100
mm. *P < 0.05 versus parental and sham cells. Sc,
sham transfection; Sh, shRNA transfection.
Pancreatic CSCs in Metastatic FociPANC-lung cells and the sham-transfected clones (Sc-1 and
Sc-10) (Figure 7C). PANC-lung and sham-transfected clones
exhibited nondescript red nodules in lung, indicative of
hemorrhage or congestion due to the presence of pulmonary
metastases (Figure 7D). Moreover, the percentage of HLAþ
area in liver and lung was signiﬁcantly decreased in Sh-1 and
Sh-2 lesions, compared with the lesions caused by the cor-
responding control cells (Figure 7, E and F). IHC analysis of
nestin in liver conﬁrmed decreased nestin expression in
shRNA-transfected clones (Figure 7G). Thus, increased
nestin expression in metastatic cells plays important roles in
tumor metastasis, and inhibition of nestin expression in
pancreatic cancer cells could suppress metastasis.
Next, we determined the effects of nestin shRNA in KLM-
1 and PK-8 cells, which express low or very low nestin levels
(Supplemental Figure S7G). In these cells, nestin shRNA did
not alter cell migration or sphere formation (Supplemental
Figure S7, H and I). Thus, the effects of nestin shRNA were
not due to nonspeciﬁc effects on pancreatic cancer cells.The American Journal of Pathology - ajp.amjpathol.orgAnalyses of Inﬂammatory Cells in PDAC Tissue
The failure of nude mice (which are not as severely
immunodeﬁcient as NOG mice) to develop metastases
after intrasplenic injection of human PDAC cells raised
the possibility that the immune system could be activated
to suppress metastatic disease. To examine this possibility,
IHC analysis was performed to detect macrophages (CD68
for human and MAC-2 for mouse), T cells (CD3), B cells
(CD20), and dendritic cells (CD11c) in human hepatic
metastases, in metastatic lesions in NOG mice after
intrasplenic injection of PDAC cells, and in nude mice
after orthotopic injection of these cells (Supplemental
Figure S8). Hepatic metastases in human PDAC and in
an orthotopic model in nude mice exhibited marked
inﬁltration of the metastatic lesions by macrophages and
slight inﬁltration with T cells and B cells. By contrast,
there were only a few MAC-2þ macrophages in the he-
patic metastases in NOG mice, and no natural killer cells683
Matsuda et alwere detected in liver tissues from nude and NOG mice
(data not shown).
Discussion
The intrasplenic model of PDAC consists of the injection of
cancer cells into the spleen and removal of the spleen 1
minute later, which allows sufﬁcient time for the cancer
cells to ﬂow from the spleen into the splenic vein, and then into
the portal vein and liver.15 Although this is not a frequently
used model, it can provide important information on the met-
astatic process. In the present study, at 1 day after intrasplenic
injection of human PDAC cells, HLAþ PDAC cells were
detected in liver of nude andNOGmice, but not inother organs,
suggesting that the cancer cells may be trapped in the liver
immediately after injection and only later disseminate to other
organs. In the NOGmice, sites of metastasis included lung and
kidney, which are known sites for PDACmetastasis, as well as
the heart, which is a less frequent metastatic site.16 Metastases
to pancreas were also observed in these mice, underscoring the
observation that PDAC may also form intrapancreatic metas-
tases,17 and that certain cancers (eg, lung, kidney, and breast
cancers) may metastasize to normal pancreas.18
Surprisingly, nude mice did not develop metastases after
intrasplenic injection of human PDAC cells, even though
they readily formed metastases after intrapancreatic injec-
tion. Moreover, metastatic lesions in human PDAC and in
an orthotopic nude mouse model contained many inﬁltrating
macrophages, whereas the metastatic lesions in NOG mice
harbored only a paucity of inﬁltrating macrophages. Taken
together, these observations raise the possibility that the
immune system could be activated in PDAC patients to
suppress metastatic disease.
Human PDAC cells derived from metastatic liver and lung
tumors of NOG mice uniformly formed metastatic foci after
tail-vein injection and exhibited increased sphere formation
and side-population fraction, attenuated proliferation, and
increased expression of the CSC markers ALDH1A1, nestin,
and ABCG2. Nestin and ABCG2 levels were especially
elevated in lung metastases, and nearly all tested metastatic
lesions in PDAC patients exhibited increased ABCG2 and
nestin expression. Moreover, the CSC fraction was high in
early hepatic metastases, but decreased with time. Taken
together, these ﬁndings indicate that the cancer cells isolated
from metastatic lesions in NOG mice have many of the fea-
tures associated with CSCs, and suggest that metastatic CSCs
can convert to nonstem cancer cells, which is in agreement
with recent concepts regarding active CSC plasticity whereby
nonstem cancer cells can acquire CSC features and CSCs can
lose their stem cell characteristics.19 It is also possible that
nestinþ cells metastasize out of the liver, explaining both their
decreased prevalence with time in liver lesions and their
abundance in distant metastases.
Nestin is a class VI intermediate ﬁlament protein that re-
quires other intermediate ﬁlament proteins to form ﬁlamentous
structures.20 Nestin is also a stem-cell marker, and activation684of oncogenic K-ras in the nestin cell lineage in the pancreas
leads to pancreatic intraepithelial neoplasia that progresses to
PDAC after an acute inﬂammatory insult.21 Moreover, we
have previously reported that nestin contributes to pancreatic
cancer cell migration, invasion, and metastasis via alterations
in E-cadherin and F-actin, and that restoring nestin expression
in shRNA-transfected PANC-1 and PK-45H cells leads to
enhanced invasive behavior.9 In the present study, we
demonstrated that expression levels of slug, a major EMT-
associated transcription factor, was regulated by nestin in
PANC-1 cells. We also determined that highly metastatic
pancreatic cancer cells express nestin in both mouse and
human metastatic lesions, and that nestin expression correlates
with EMT and CSC features. Moreover, suppression of nestin
expression was associated with a marked decrease in sphere
formation in vitro and metastatic potential in vivo. Taken
together, our ﬁndings conﬁrm that nestin is a CSC marker in
PDAC, and suggest that targeting nestin could help suppress
CSCs and metastasis in PDAC. Inasmuch as pancreatic CSCs
contribute to PDAC growth and chemoresistance, and their
resistance can be partially overcome by targeting the pathways
that promote CSCs,22e24 our ﬁndings also suggest that tar-
geting nestin could be an important component of various
combinational therapeutic strategies in PDAC.
Cell attachment to the extracellular matrix was increased
in metastasis-derived pancreatic cancer cells, but these cells
exhibited enhanced motility (especially the cancer cells
derived from lung metastases). Invasion through Matrigel
was also increased in the metastatic cancer cells, and both
increased migration and invasion were associated with
features consistent with EMT, as evidenced by decreased
E-cadherin mRNA and protein levels and by the large,
polygonal features of these cells. These ﬁndings suggest that
cancer cell heterogeneity may correlate with the presence of
CSCs, which help to promote distant metastases.25,26 Given
that EMT and stemness have a close causal relationship,27
our ﬁndings further underscore the potential beneﬁt of tar-
geting nestin to increase therapeutic effectiveness in PDAC.
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